JP7295034B2 - 癌関連障害の治療のためのキナゾリン-ピリジン誘導体 - Google Patents

癌関連障害の治療のためのキナゾリン-ピリジン誘導体 Download PDF

Info

Publication number
JP7295034B2
JP7295034B2 JP2019560299A JP2019560299A JP7295034B2 JP 7295034 B2 JP7295034 B2 JP 7295034B2 JP 2019560299 A JP2019560299 A JP 2019560299A JP 2019560299 A JP2019560299 A JP 2019560299A JP 7295034 B2 JP7295034 B2 JP 7295034B2
Authority
JP
Japan
Prior art keywords
alkyl
group
pharmaceutically acceptable
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019560299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518627A (ja
JP2020518627A5 (cg-RX-API-DMAC10.html
Inventor
レディ レレティ マンモハン
ハーディング.マイルズ ディロン
パトリック パワーズ ジェイ
リード ローゼン ブランドン
ユイ シャリフ エヘサン
トマストラン リアノン
Original Assignee
アーカス バイオサイエンシズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーカス バイオサイエンシズ インコーポレイティド filed Critical アーカス バイオサイエンシズ インコーポレイティド
Publication of JP2020518627A publication Critical patent/JP2020518627A/ja
Publication of JP2020518627A5 publication Critical patent/JP2020518627A5/ja
Application granted granted Critical
Publication of JP7295034B2 publication Critical patent/JP7295034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019560299A 2017-05-05 2018-05-03 癌関連障害の治療のためのキナゾリン-ピリジン誘導体 Active JP7295034B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762502391P 2017-05-05 2017-05-05
US62/502,391 2017-05-05
US201862624273P 2018-01-31 2018-01-31
US62/624,273 2018-01-31
PCT/US2018/030909 WO2018204661A1 (en) 2017-05-05 2018-05-03 Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Publications (3)

Publication Number Publication Date
JP2020518627A JP2020518627A (ja) 2020-06-25
JP2020518627A5 JP2020518627A5 (cg-RX-API-DMAC10.html) 2022-08-12
JP7295034B2 true JP7295034B2 (ja) 2023-06-20

Family

ID=64016681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560299A Active JP7295034B2 (ja) 2017-05-05 2018-05-03 癌関連障害の治療のためのキナゾリン-ピリジン誘導体

Country Status (9)

Country Link
US (1) US11045472B2 (cg-RX-API-DMAC10.html)
EP (1) EP3618829B1 (cg-RX-API-DMAC10.html)
JP (1) JP7295034B2 (cg-RX-API-DMAC10.html)
CN (1) CN110612100B (cg-RX-API-DMAC10.html)
ES (1) ES2953349T3 (cg-RX-API-DMAC10.html)
PL (1) PL3618829T3 (cg-RX-API-DMAC10.html)
TW (1) TWI789393B (cg-RX-API-DMAC10.html)
UY (1) UY37725A (cg-RX-API-DMAC10.html)
WO (1) WO2018204661A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110636846B (zh) * 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
CN109293586A (zh) * 2018-11-22 2019-02-01 云南师范大学 一种在氨水中微波条件下卤代苯甲酸合成喹唑啉酮化合物的方法
WO2020146563A1 (en) * 2019-01-10 2020-07-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
AU2021213969A1 (en) * 2020-01-30 2022-09-01 ONA Therapeutics S.L. Combination therapy for treatment of cancer and cancer metastasis
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
EP4341262A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
TW202325279A (zh) 2021-10-29 2023-07-01 美商阿克思生物科學有限公司 HIF-2α抑制劑及其使用方法
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN119462487A (zh) * 2023-08-08 2025-02-18 重庆博腾制药科技股份有限公司 一种阿培利司中间体4-甲基吡啶类化合物的制备方法
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
EP4788432A1 (en) 2023-10-06 2026-08-12 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same
WO2026035034A1 (ko) * 2024-08-06 2026-02-12 주식회사 대웅제약 신규한 퀴나졸린 유도체 및 이를 포함하는 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535404A (ja) 2001-05-24 2004-11-25 イーライ・リリー・アンド・カンパニー 医薬物質としての新規ピロール誘導体
JP2006515316A (ja) 2003-05-06 2006-05-25 シーブイ・セラピューティクス・インコーポレイテッド A2bアデノシンレセプターアンタゴニストであるキサンチン誘導体
JP2012515759A (ja) 2009-01-26 2012-07-12 ドマン・テラプーテイツク 新規なアデノシン受容体リガンドおよびその使用
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330183B (cg-RX-API-DMAC10.html) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CA2551944A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
TW200813056A (en) * 2006-06-29 2008-03-16 King Pharmaceuticals Res Dev Inc Adenosine A2B receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2010033906A2 (en) * 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535404A (ja) 2001-05-24 2004-11-25 イーライ・リリー・アンド・カンパニー 医薬物質としての新規ピロール誘導体
JP2006515316A (ja) 2003-05-06 2006-05-25 シーブイ・セラピューティクス・インコーポレイテッド A2bアデノシンレセプターアンタゴニストであるキサンチン誘導体
JP2012515759A (ja) 2009-01-26 2012-07-12 ドマン・テラプーテイツク 新規なアデノシン受容体リガンドおよびその使用
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist

Also Published As

Publication number Publication date
US20200069689A1 (en) 2020-03-05
PL3618829T3 (pl) 2023-11-20
US11045472B2 (en) 2021-06-29
CN110612100A (zh) 2019-12-24
EP3618829B1 (en) 2023-06-07
EP3618829A1 (en) 2020-03-11
TWI789393B (zh) 2023-01-11
EP3618829A4 (en) 2021-01-06
ES2953349T3 (es) 2023-11-10
UY37725A (es) 2018-10-31
JP2020518627A (ja) 2020-06-25
EP3618829C0 (en) 2023-06-07
TW201843150A (zh) 2018-12-16
CN110612100B (zh) 2023-04-14
WO2018204661A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CN110612100B (zh) 治疗与癌症有关疾病的喹唑啉-吡啶衍生物
JP7394831B2 (ja) ピリドンa2rアンタゴニスト
JP7021282B2 (ja) 癌関連障害の治療のためのアゾロピリミジン
JP7189155B2 (ja) 癌関連障害の治療のためのキナゾリン-ピラゾール誘導体
KR20220047247A (ko) 2,3,5-삼치환 피라졸로[1,5-a]피리미딘 화합물
CN111818928A (zh) 精氨酸酶抑制剂
HK40055891B (zh) 吡啶酮a2r拮抗剂
HK40105495A (en) Azolopyrimidine for the treatment of cancer-related disorders
HK40101362A (en) Azolopyrimidine for the treatment of cancer-related disorders
HK40024629A (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40024629B (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40054296A (en) Pyridone a2r antagonists
HK40054296B (en) Pyridone a2r antagonists
HK40055891A (en) Pyridone a2r antagonists
EA038488B1 (ru) Азолопиримидины для лечения раковых заболеваний
HK40068316B (zh) 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210506

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220607

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230608

R150 Certificate of patent or registration of utility model

Ref document number: 7295034

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150